Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as an injectable treatment for complicated urinary tract infections (cUTI), including acute pyelonephritis.
According to the manufacturer, Contepo is the first intravenously administered epoxide therapy in the US.
